Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 juin 2011 16h05 HE | Source: Zogenix

Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference

SAN DIEGO, June 13, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
27 mai 2011 07h30 HE | Source: Zogenix

Zogenix to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June

SAN DIEGO, May 27, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that additional data from the Company's Phase 4 clinical study of SUMAVEL® DosePro® (sumatriptan...
25 mai 2011 07h30 HE | Source: Zogenix

Zogenix Stockholders Elect Mark Wiggins to Board of Directors

SAN DIEGO, May 25, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
18 mai 2011 07h30 HE | Source: Zogenix

Zogenix Highlights DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference

SAN DIEGO, May 18, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it presented three posters highlighting its proprietary DosePro® Needle-free Delivery System (DosePro)...
16 mai 2011 16h00 HE | Source: Zogenix

Zogenix Reports First Quarter 2011 Financial Results

Confirms 2011 Financial Guidance Conference Call and Web cast Today, May 16th, at 4:30 p.m. ET SUMAVEL® DosePro® U.S. Highlights First quarter 2011 U.S. net product revenue of...
11 mai 2011 07h30 HE | Source: Zogenix

Zogenix to Highlight DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference

SAN DIEGO, Calif., May 11, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that it will present three posters highlighting its proprietary DosePro® Needle-free Delivery...
04 mai 2011 16h53 HE | Source: Zogenix

Zogenix to Hold Conference Call to Discuss First Quarter 2011 Financial Results

SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the first quarter ended March 31, 2011 after market close on Monday, May...
13 avr. 2011 07h30 HE | Source: Zogenix

Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks

SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today reported clinical data from its Phase 4 open-label, multicenter study of SUMAVEL® DosePro ® (sumatriptan...
12 avr. 2011 07h30 HE | Source: Zogenix

Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program

SAN DIEGO, April 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL® DosePro® (sumatriptan injection)...
16 mars 2011 07h30 HE | Source: Zogenix

Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years

SAN DIEGO, March 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...

Page précédente